Publications by authors named "Alexander D Heini"
Introduction: The growing body of evidence around sexual and gender dimorphism in medicine, particularly in oncology, has highlighted differences in treatment response, outcomes, and side effects between males and females. Differences in drug metabolism, distribution, and elimination, influenced by factors like body composition and enzyme expression, contribute to these variations.
Methods: We retrospectively analyzed data of 112 multiple myeloma (MM) patients treated with first-line high-dose chemotherapy (HDCT) with treosulfan and melphalan (TreoMel) followed by autologous stem cell transplantation (ASCT) at a single academic center between January 2020 and August 2022.
Article Synopsis
- Bispecific antibodies, like talquetamab, have improved treatment options for multiple myeloma by redirecting T cells to target specific cancer cells.
- Talquetamab targets GPRC5D, leading to skin toxicity, which poses challenges for patient management.
- A case study revealed that a patient experienced severe skin toxicity from talquetamab following a stem cell treatment, highlighting the need for personalized care in using novel immunotherapies alongside traditional treatments.
Article Synopsis
- Personalized treatment options for patients with diffuse large B-cell lymphoma (DLBCL) are being developed, with a focus on specific treatments for different patient groups.
- Caracciolo et al. investigate UMG1, a specific part of the CD43 protein, as a potential therapeutic target and find encouraging results with an Anti-UMG1-antibody in preclinical studies.
- The study highlights the use of a bispecific T-cell engager (BTCE) that redirects T-cell activity to effectively target DLBCL.
High-dose chemotherapy (HDCT) with autologous stem cell transplantation (ASCT) is an option to consolidate remission in Waldenstrom's macroglobulinemia (WM), particularly in selected younger patients with chemosensitive disease. BEAM, consisting of BCNU, etoposide, cytarabine, and melphalan, is often used as a conditioning regimen. However, problems with BCNU, including pneumotoxicity, tolerance, and availability, necessitate the search for alternatives.
View Article and Find Full Text PDFArticle Synopsis
- Mantle cell lymphoma (MCL) is a rare and aggressive type of B-cell Non-Hodgkin lymphoma that primarily affects men, with most patients experiencing relapses after initial treatments.
- Recent advancements, including the use of CAR T therapy, have improved survival rates, but options for patients who relapse post-CAR T are still limited.
- Two cases of patients who relapsed after CAR T therapy were treated with the bispecific antibody glofitamab, resulting in increased CAR T cells and positive responses, suggesting this therapy could be a promising option for similar cases.
Introduction: Despite a 50% cure rate, relapse remains the main cause of death in patients with acute myeloid leukemia (AML) consolidated with autologous stem cell transplantation (ASCT) in first remission (CR1). Clonal hematopoiesis of indeterminate potential (CH) increases the risk for hematological and cardiovascular disorders and death. The impact of CH persisting after ASCT in AML patients is unclear.
View Article and Find Full Text PDFArticle Synopsis
- High levels of acute phase proteins can indicate worse outcomes in various cancers, but their impact on acute myeloid leukemia (AML) wasn't previously understood.
- Researchers studied 282 newly diagnosed AML patients undergoing chemotherapy and created a new score, the CFA ratio, based on C-reactive protein, fibrinogen, and albumin levels.
- Patients with a CFA ratio below 3.06 had significantly better progression-free, disease-free, and overall survival rates, suggesting that elevated CFA ratios and modified Glasgow prognostic scores are linked to poorer outcomes in AML, warranting further evaluation for risk assessment.
The outcome of AML patients ≥65 years remains disappointing. Current post-induction strategies for elderly AML patients fit for intensive treatment involve additional cycles of chemotherapy or allogeneic transplantation. Consolidation with autologous transplantation (ASCT) is poorly studied in these patients.
View Article and Find Full Text PDFIncreased plasma fibrinogen levels are associated with shortened overall survival (OS) in some solid tumor types. In contrast, the prognostic significance of varying fibrinogen levels in acute myeloid leukemia (AML) at diagnosis is unknown. In this study, we assessed the prognostic significance of fibrinogen levels in AML patients.
View Article and Find Full Text PDF